Isolated Hepatic Perfusion for the Treatment of Liver Metastases

Current Problems in Cancer

Volumn 36, Issue 2, 2012, Pages 27-76

  Boone, Brian A ^a   Bartlett, David L ^a   Zureikat, Amer H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MELPHALAN; MITOMYCIN C; OXALIPLATIN;

ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CHEMOEMBOLIZATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXICITY; HUMAN; HYPERTHERMIA; INFUSION PUMP; INOPERABLE CANCER; LIVER METASTASIS; LIVER PERFUSION; LONG TERM SURVIVAL; MAXIMUM TOLERATED DOSE; MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; SURGICAL TECHNIQUE; SYSTEMIC CIRCULATION; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPOTHERMIA, INDUCED; INFUSION PUMPS; LIVER NEOPLASMS;

EID: 84859179114     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2011.12.001     Document Type: Article

References (207)

1. DeVita V.T. Dose-response is alive and well. J Clin Oncol 1986, 4:1157-1159.
2. Hryniuk W.M. Is more better?. J Clin Oncol 1986, 4:621-622.
3. Hryniuk W.M. More is better. J Clin Oncol 1988, 6:1365-1367.
4. Hryniuk W., Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986, 4:1162-1170.
5. Surbone A., DeVita V.T. Dose intensity. The neglected variable in clinical trials. Ann NY Acad Sci 1993, 698:279-288.
6. Tiong L., Maddern G.J. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2010, 98:1210-1224.
7. Guenette J.P., Dupuy D.E. Radiofrequency ablation of colorectal hepatic metastases. J Surg Oncol 2010, 102:978-987.
8. Bleicher R.J., Allegra D.P., Nora D.T., et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003, 10:52-58.
9. Howard J.H., Tzeng C.W., Smith J.K., et al. Radiofrequency ablation for unresectable tumors of the liver. Am Surg 2008, 74:594-600. [Discussion 591-600].
10. Eisele R.M., Neumann U., Neuhaus P., et al. Open surgical is superior to percutaneous access for radiofrequency ablation of hepatic metastases. World J Surg 2009, 33:804-811.
11. Kuvshinoff B.W., Ota D.M. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002, 132:605-611. [Discussion 602-11].
12. Kingham T.P., Tanoue M., Eaton A., et al. Patterns of recurrence after ablation of colorectal cancer Liver metastases. Ann Surg Oncol 2011 Aug 31, [Epub ahead of print].
13. Wong S.L., Mangu P.B., Choti M.A., et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010, 28:493-508.
14. Aloia T.A., Vauthey J.N., Loyer E.M., et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006, 141:460-466. [Discussion 466-7].
15. Otto G., Düber C., Hoppe-Lotichius M., et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010, 251:796-803.
16. Goldberg S.N., Kamel I.R., Kruskal J.B., et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002, 179:93-101.
17. Gan Y.H., Yie S.L., Ren Z.G., et al. Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma. Zhonghua Zhong liu za zhi. Chin J Oncol 2004, 26:496-498.
18. Jiao L.R., Hansen P.D., Havlik R., et al. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg 1999, 177:303-306.
19. Breedis C., Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969-977.
20. Sullivan R.D., Norcross J.W., Watkins E. Chemotherapy of metastatic Liver cancer by prolonged hepatic-artery infusion. N Engl J Med 1964, 270:321-327.
21. Kemeny N., Seiter K., Niedzwiecki D., et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992, 69:327-334.
22. Allen P.J., Nissan A., Picon A.I., et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005, 201:57-65.
23. Shao Y.Y., Huang C.C., Liang P.C., et al. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010, 6:80-88.
24. Melichar B., Voboril Z., Lojik M., et al. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepato Gastroenterol 2009, 56:1157-1162.
25. Melichar B., Voboril Z., Nozicka J., et al. Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases. Tumori 2005, 91:19-23.
26. Tsimberidou A.M., Letourneau K., Fu S., et al. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 2011, 68:247-253.
27. Kingham T.P., D'Angelica M., Kemeny N.E. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol 2010, 102:988-995.
28. Kemeny M.M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002, 20:1499-1505.
29. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039-2048.
30. Lorenz M., Müller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998, 228:756-762.
31. Lygidakis N.J., Sgourakis G., Vlachos L., et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001, 48:1685-1691.
32. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008, 15:219-226.
33. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005, 23:4881-4887.
34. Goéré D., Deshaies I., de Baere T., et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010, 251:686-691.
35. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009, 27:3465-3471.
36. Mocellin S., Pilati P., Lise M., et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 2007, 25:5649-5654.
37. Bouchahda M., Levi F., Adam R., et al. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer 2011, 47:2681-2690.
38. Giroux M.F., Baum R.A., Soulen M.C. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 2004, 15:289-291.
39. Fromigué J., De Baere T., Baudin E., et al. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:2496-2499.
40. Roche A., Girish B.V., de Baère T., et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003, 13:136-140.
41. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005, 104:1590-1602.
42. Gupta S., Bedikian A.Y., Ahrar J., et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol 2010, 33:474-480.
43. Mavligit G.M., Charnsangavej C., Carrasco C.H., et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988, 260:974-976.
44. Sharma K.V., Gould J.E., Harbour J.W., et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 2008, 190:99-104.
45. Salman H.S., Cynamon J., Jagust M., et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002, 2:173-179.
46. Sharma R.A., Wasan H.S., Love S.B., et al. Foxfire: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol (R Coll Radiol) 2008, 20:261-263.
47. Liapi E., Geschwind J.F. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?. Cardiovasc Interv Radiol 2011, 34:37-49.
48. Chen M.S., Li J.Q., Zhang Y.Q., et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002, 8:74-78.
49. Carter S., Martin Ii R.C. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford) 2009, 11:541-550.
50. de Brauw L.M., Marinelli A., van de Velde C.J., et al. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res 1991, 51:1694-1700.
51. Pass H.I., Mew D.J., Kranda K.C., et al. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg 1996, 61:1609-1617.
52. Walther M.M., Jennings S.B., Choyke P.L., et al. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol 1996, 14(Suppl 1):S2-S7.
53. Deroose J.P., Grünhagen D.J., van Geel A.N., et al. Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br J Surg 2011, 98:1573-1580.
54. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616-632.
55. Ausman R.K. Development of a technic for isolated perfusion of the liver. NY State J Med 1961, 61:3993-3997.
56. Schwemmle K., Link K.H., Rieck B. Rationale and indications for perfusion in liver tumors: current data. World J Surg 1987, 11:534-540.
57. Aigner K., Walther H., Tonn J., et al. First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. Recent results in cancer research. Fortschr Krebsforsch 1983, 86:99-102.
58. Alexander H.R., Butler C.C. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010, 16:132-141.
59. Feldman E.D., Wu P.C., Beresneva T., et al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 2004, 8:200-207.
60. Alexander H.R., Bartlett D.L., Libutti S.K., et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 2009, 16:1852-1859.
61. van Iersel L.B., Gelderblom H., Vahrmeijer A.L., et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 2008, 19:1127-1134.
62. Libutti S.K., Barlett D.L., Fraker D.L., et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 2000, 191:519-530.
63. Marinelli A., de Brauw L.M., Beerman H., et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996, 26:341-350.
64. Verhoef C., de Wilt J.H., Brunstein F., et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol 2008, 15:1367-1374.
65. Skarsgard L.D., Skwarchuk M.W., Vinczan A., et al. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995, 15:219-223.
66. Rothbarth J., Sparidans R.W., Beijnen J.H., et al. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake. J Pharmacol Exp Ther 2002, 303:736-740.
67. Barker W.C., Andrich M.P., Alexander H.R., et al. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995, 22:1242-1248.
68. Miao N., Pingpank J.F., Alexander H.R., et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008, 15:815-823.
69. Beheshti M.V., Denny D.F., Glickman M.G., et al. Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. J Vasc Interv Radiol 1992, 3:453-458.
70. Curley S.A., Byrd D.R., Newman R.A., et al. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: a feasibility study of a novel system. Anticancer Drugs 1991, 2:175-183.
71. Pingpank J.F., Libutti S.K., Chang R., et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005, 23:3465-3474.
72. Curley S.A., Newman R.A., Dougherty T.B., et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1994, 1:389-399.
73. Ravikumar T.S., Pizzorno G., Bodden W., et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994, 12:2723-2736.
74. Savier E., Azoulay D., Huguet E., et al. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. Arch Surg 2003, 138:325-332.
75. Eggermont A.M., van IJken M.G., van Etten B., et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000, 47:776-781.
76. van Etten B., Brunstein F., van IJken M.G., et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 2004, 11:598-605.
77. Bartlett D.L., Libutti S.K., Figg W.D., et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001, 129:176-187.
78. Alexander H.R., Libutti S.K., Pingpank J.F., et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005, 12:138-144.
79. van Iersel L.B., Verlaan M.R., Vahrmeijer A.L., et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol 2007, 33:874-881.
80. Less J.R., Posner M.C., Boucher Y., et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992, 52:6371-6374.
81. Alexander H.R., Brown C.K., Bartlett D.L., et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res 1998, 4:2357-2362.
82. Gnant M.F., Noll L.A., Terrill R.E., et al. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery 1999, 126:890-899.
83. Skitzki J.J., Repasky E.A., Evans S.S. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 2009, 10:550-558.
84. Engin K. Biological rationale and clinical experience with hyperthermia. Control Clin Trials 1996, 17:316-342.
85. Moyer H.R., Delman K.A. The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperthermia 2008, 24:251-261.
86. Nagata Y., Hiraoka M., Nishimura Y., et al. Clinical results of radiofrequency hyperthermia for malignant liver tumors. Int J Radiat Oncol Biol Phys 1997, 38:359-365.
87. Hahn G.M., Braun J., Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975, 72:937-940.
88. Zhang L., Yang Y., Wei X.Y., et al. Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with interferon alpha and verapamil. J Exp Clin Cancer Res 2007, 26:201-207.
89. Skibba J.L., Quebbeman E.J. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg 1986, 121:1266-1271.
90. Mocellin S., Pilati P., Da Pian P., et al. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Ann Surg Oncol 2007, 14:802-809.
91. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52-60.
92. Bates D.A., Mackillop W.J. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer 1990, 62:183-188.
93. Pilati P., Mocellin S., Rossi C.R., et al. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function. World J Surg 2004, 28:775-781.
94. Alexander H.R., Bartlett D.L., Libutti S.K., et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998, 16:1479-1489.
95. Rothbarth J., Pijl M.E., Vahrmeijer A.L., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003, 90:1391-1397.
96. van Iersel L.B., Hoekman E.J., Gelderblom H., et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 2008, 15:1891-1898.
97. van Iersel L.B., Koopman M., van de Velde C.J., et al. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 2010, 21:1662-1667.
98. Vahrmeijer A.L., van Dierendonck J.H., Keizer H.J., et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000, 82:1539-1546.
99. Alexander H.R., Libutti S.K., Bartlett D.L., et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 2002, 95:730-736.
100. Alexander H.R., Libutti S.K., Bartlett D.L., et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000, 6:3062-3070.
101. de Vries M.R., Borel Rinkes I.H., van de Velde C.J., et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent results in cancer research. Fortschr Krebsforsch 1998, 147:107-119.
102. Lindnér P., Fjälling M., Hafström L., et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 1999, 25:179-185.
103. Rizell M., Mattson J., Cahlin C., et al. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res 2008, 18:120-126.
104. Kuppen P.J., Jonges L.E., van de Velde C.J., et al. Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Br J Cancer 1997, 75:1497-1500.
105. de Wilt J.H., ten Hagen T.L., de Boeck G., et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000, 82:1000-1003.
106. Olieman A.F., van Ginkel R.J., Hoekstra H.J., et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997, 4:64-69.
107. Hoving S., Seynhaeve A.L., van Tiel S.T., et al. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 2006, 17:949-959.
108. van Etten B., de Vries M.R., van IJken M.G., et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 2003, 88:314-319.
109. Cornett W.R., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol 2006, 24:4196-4201.
110. Lans T.E., Bartlett D.L., Libutti S.K., et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 2001, 7:784-790.
111. De Vries M.R., Borel Rinkes I.H., Swaak A.J., et al. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. Eur J Clin Invest 1999, 29:553-560.
112. Oldhafer K.J., Lang H., Kuse E.R., et al. High-dose tumor necrosis factor-alpha leads to the systemic inflammatory response syndrome. Am J Med 1998, 105:346-347.
113. Kelley S.T., Menon C., Buerk D.G., et al. Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery 2002, 132:252-258.
114. Grothey A. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. Oncology 2010, 79:389-399.
115. Fiorentini G., Rossi S., Dentico P., et al. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I-II clinical study. Anticancer Res 2004, 24:2093-2096.
116. Kern W., Beckert B., Lang N., et al. Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response. Anticancer Res 2000, 20:4973-4975.
117. Mancuso A., Giuliani R., Accettura C., et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 2003, 23:1917-1922.
118. Piché N., Leblond F.A., Sidéris L., et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg 2011, 254:138-144.
119. Rietbroek R.C., van de Vaart P.J., Haveman J., et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997, 123:6-12.
120. Zeh H.J., Brown C.K., Holtzman M.P., et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 2009, 16:385-394.
121. Graham M.A., Lockwood G.F., Greenslade D., et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000, 6:1205-1218.
122. Synold T.W., Takimoto C.H., Doroshow J.H., et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007, 13:3660-3666.
123. Takimoto C.H., Graham M.A., Lockwood G., et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007, 13:4832-4839.
124. Bradner W.T. Mitomycin C: a clinical update. Cancer Treat Rev 2001, 27:35-50.
125. Aigner KR W.H., Link K.H. Isolated liver perfusion with MMC/5-FU: surgical technique pharmacokinetics, clinical results. Contr Oncol 1988, 29:229-246.
126. Marinelli A., Vahrmeijer A.L., van de Velde C.J. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent results in cancer research. Fortschr Krebsforsch 1998, 147:83-94.
127. Aigner K., Walther H., Tonn J.C., et al. Isolated liver perfusion with 5-fluorouracil (5-FU) in the human. Chirurgie 1982, 53:571-573.
128. Breithaupt H., Aigner K., Hechtel R. Kinetics of methotrexate, dacarbazine and 5-fluorouracil during isolated liver perfusion. Recent results in cancer research. Fortschr Krebsforsch 1983, 86:116-121.
129. Colorectal Cancer Facts and Figures 2011-2013 2011, American Cancer Society, American Cancer Society, Atlanta, GA.
130. Lahr C.J., Soong S.J., Cloud G., et al. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1983, 1:720-726.
131. Rougier P., Milan C., Lazorthes F., et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg 1995, 82:1397-1400.
132. Choti M.A., Bulkley G.B. Management of hepatic metastases. Liver Transplant Surg 1999, 5:65-80.
133. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759-766.
134. Ercolani G., Grazi G.L., Ravaioli M., et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch Surg 2002, 137:1187-1192.
135. Kato T., Yasui K., Hirai T., et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003, 46:S22-S31.
136. Nesbitt C., Glendinning R.J., Byrne C., et al. Factors that influence treatment strategies in advanced colorectal cancer. Eur J Surg Oncol 2007, 33(Suppl 2):S88-S94.
137. Wicherts D.A., de Haas R.J., Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 2007, 33(Suppl 2):S42-S51.
138. Abdalla E.K., Adam R., Bilchik A.J., et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006, 13:1271-1280.
139. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059-2069.
140. Haller D.G., Rothenberg M.L., Wong A.O., et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008, 26:4544-4550.
141. Rigel D.S. Trends in dermatology: melanoma incidence. Arch Dermatol 2010, 146:318.
142. Singh A.D., Bergman L., Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005, 18:75-84. viii.
143. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report Number 15. Arch Ophthalmol 2001, 119:670-676. Collaborative Ocular Melanoma Study Group.
144. Papastefanou V.P., Cohen V.M. Uveal melanoma. Skin Cancer 2011, 2011:573974.
145. Diener-West M., Reynolds S.M., Agugliaro D.J., et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report No. 26. Arch Ophthalmol 2005, 123:1639-1643.
146. Albert D.M., Ryan L.M., Borden E.C. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996, 114:107-108.
147. Thibault C., Sagar P., Nivatvongs S., et al. Anorectal melanoma-an incurable disease?. Dis Colon Rectum 1997, 40:661-668.
148. Kivelä T., Suciu S., Hansson J., et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003, 39:1115-1120.
149. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125.
150. Pyrhönen S., Hahka-Kemppinen M., Muhonen T., et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 2002, 95:2366-2372.
151. Caralt M., Martí J., Cortés J., et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2011, 18:268-275.
152. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010, 37:127-138.
153. Ahrar J., Gupta S., Ensor J., et al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 2011, 29:49-55.
154. Schuster R., Lindner M., Wacker F., et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010, 20:191-196.
155. Brown R.E., Gibler K.M., Metzger T., et al. Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: early outcomes from a multi-institutional registry. Am Surg 2011, 77:93-98.
156. Leyvraz S., Spataro V., Bauer J., et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997, 15:2589-2595.
157. Voelter V., Schalenbourg A., Pampallona S., et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008, 18:220-224.
158. Peters S., Voelter V., Zografos L., et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006, 17:578-583.
159. Phase III Randomized Study of Fotemustine Administered as an Intravenous Infusion Versus an Intra-Arterial Hepatic Perfusion in Patients with Surgically Incurable or Unresectable Liver Metastases Secondary to Uveal Melanoma 2011, National Cancer Institute, European Organization for Research and Treatment of Cancer (EORTC), NCT00110123.
160. Siegel R., Hauschild A., Kettelhack C., et al. Hepatic arterial fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007, 33:627-632.
161. Alexander H.R., Libutti S.K., Pingpank J.F., et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003, 9:6343-6349.
162. Elias D., Lasser P., Ducreux M., et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003, 133:375-382.
163. Steinmüller T., Kianmanesh R., Falconi M., et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87:47-62.
164. Eriksson B., Arnberg H., Lindgren P.G., et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990, 228:103-113.
165. Gedaly R., Daily M.F., Davenport D., et al. Liver transplantation for the treatment of Liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011, 146:953-958.
166. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22:4762-4771.
167. Kennedy A.S., Dezarn W.A., McNeillie P., et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008, 31:271-279.
168. Rhee T.K., Lewandowski R.J., Liu D.M., et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008, 247:1029-1035.
169. Karabulut K., Akyildiz H.Y., Lance C., et al. Multimodality treatment of neuroendocrine liver metastases. Surgery 2011, 150:316-325.
170. Akyildiz H.Y., Mitchell J., Milas M., et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010, 148:1288-1293. [Discussion 1293].
171. Grover A.C., Libutti S.K., Pingpank J.F., et al. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 2004, 136:1176-1182.
172. Venook A.P., Papandreou C., Furuse J., et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl 4):5-13.
173. Olthoff K.M. Surgical options for hepatocellular carcinoma: resection and transplantation. Liver Transplant Surg 1998, 4:S98-S104.
174. Edeline J., Raoul J.L., Vauleon E., et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009, 15:713-716.
175. Belghiti J., Panis Y., Farges O., et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991, 214:114-117.
176. Nagasue N., Uchida M., Makino Y., et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993, 105:488-494.
177. Kagawa T., Koizumi J., Kojima S., et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 2010, 116:3638-3644.
178. Ku Y., Iwasaki T., Fukumoto T., et al. Percutaneous isolated liver chemoperfusion for treatment of unresectable malignant liver tumors: technique, pharmacokinetics, clinical results. Recent results in cancer research. Fortschr Krebsforsch 1998, 147:67-82.
179. Ku Y., Iwasaki T., Tominaga M., et al. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg 2004, 239:53-60.
180. Hafström L.R., Holmberg S.B., Naredi P.L., et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994, 3:103-108.
181. Oldhafer K.J., Frerker M.K., Lang H., et al. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. J Invest Surg 1998, 11:393-400.
182. Farabos C., Haaz M.C., Gires P., et al. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. J Pharm Sci 2001, 90:722-731.
183. Becker J.C., Terheyden P., Kämpgen E., et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002, 87:840-845.
184. van Iersel L.B., Koudijs T.M., Hoekman E.J., et al. In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines. J Surg Res 2011, 167:273-278.
185. Salnikov A.V., Iversen V.V., Koisti M., et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 2003, 17:1756-1758.
186. Pietras K., Ostman A., Sjöquist M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61:2929-2934.
187. Hoving S., Brunstein F., aan de Wiel-Ambagtsheer G., et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005, 65:4300-4308.
188. Brunstein F., Eggermont A.M., de Wiel-Ambagtsheer G., et al. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007, 14:795-801.
189. Varghese S., Xu H., Bartlett D., et al. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. Ann Surg Oncol 2010, 17:1870-1877.
190. van Etten B., Eggermont A.M., van Tiel S.T., et al. Gene therapy in in vivo isolated perfusion models. Curr Gene Ther 2005, 5:195-202.
191. Naik A.M., Chalikonda S., McCart J.A., et al. Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther 2006, 17:31-45.
192. Brooks A.D., Ng B., Liu D., et al. Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: implications for local gene therapy. Surgery 2001, 129:324-334.
193. de Roos W.K., de Wilt J.H., van Der Kaaden M.E., et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 2000, 232:814-821.
194. Maleux G., Monbaliu D., Verslype C., et al. Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model. Eur Radiol 2010, 20:2372-2380.
195. Rothbarth J., Pijl M.E., Tollenaar R.A., et al. An experimental minimally invasive perfusion technique for the treatment of liver metastases. Eur J Surg Oncol 2003, 29:757-763.
196. Christoforidis D., Antonescu C., Horisberger J., et al. Endovascular isolated hepatic perfusion under pneumoperitoneum. Eur J Surg Oncol 2006, 32:113-120.
197. Kemeny N. Management of liver metastases from colorectal cancer. Oncology 2006, 20:1161-1176. 1179 [Discussion 1179-80, 1166-85].
198. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003, 361:368-373.
199. Allen-Mersh T.G., Earlam S., Fordy C., et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344:1255-1260.
200. Martin J.K., O'Connell M.J., Wieand H.S., et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990, 125:1022-1027.
201. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990, 8:1885-1893.
202. Rougier P., Munck J.N., Elias D., et al. Intra-arterial hepatic chemotherapy with pirarubicin. Preclinical and clinical studies. Am J Clin Oncol 1990, 13(Suppl 1):S1-S4.
203. Hohn D.C., Stagg R.J., Friedman M.A., et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989, 7:1646-1654.
204. Chang A.E., Schneider P.D., Sugarbaker P.H., et al. A prospective randomized trial of regional versus systemic continuous 5-Fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685-693.
205. Kemeny N., Daly J., Reichman B., et al. Intrahepatic or systemic infusion of Fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987, 107:459-465.
206. van Etten B., de Wilt J.H., Brunstein F., et al. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol 2009, 35:539-545.
207. Noter S.L., Rothbarth J., Pijl M.E., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004, 14:67-72.